title: Defining putative glycan cancer biomarkers by MS.
abstract: For decades, the association between aberrant glycosylation and many types of cancers has been shown. However, defining the changes of glycan structures has not been demonstrated until recently. This has been facilitated by the major advances in MS and separation science, which allows the detailed characterization of glycan changes associated with cancer. MS glycomics methods have been successfully employed to compare the glycomic profiles of different human specimens collected from disease-free individuals and patients with cancer. Additionally, comparing the glycomic profiles of glycoproteins purified from specimen collected from disease-free individuals and patients with cancer has also been performed. These types of glycan analyses employing MS or LC-MS allow the characterization of native, labeled and permethylated glycans. This review discusses the different glycomic and glycoproteomic methods employed for defining glycans as cancer biomarkers of different organs, including breast, colon, esophagus, liver, lung, ovarian, pancreas and prostate.
authors.affiliation: Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, TX 79409-1061, USA. yehia.mechref@ttu.edu
authors.forename: Yehia
authors.initials: Y
authors.lastname: Mechref
authors.forename: Yunli
authors.initials: Y
authors.lastname: Hu
authors.forename: Aldo
authors.initials: A
authors.lastname: Garcia
authors.forename: Shiyue
authors.initials: S
authors.lastname: Zhou
authors.forename: Janie L
authors.initials: JL
authors.lastname: Desantos-Garcia
authors.forename: Ahmed
authors.initials: A
authors.lastname: Hussein
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D002240:Carbohydrate Sequence; D006801:Humans; D013058:Mass Spectrometry; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology; D011134:Polysaccharides / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D011134:Polysaccharides